

Anatara Lifesciences Ltd
Appendix 4D
For the half-year 31 December 2020

Anatara Lifesciences Ltd

Appendix 4D

Half-year 31 December 2020

Name of entity:	Anatara Lifesciences Ltd
ABN:	41 145 239 872
Half-year ended:	31 December 2020
Previous period:	31 December 2019

Results for announcement to the market

				\$
Revenue for ordinary activities	Up	64.3%	to	685,611
Net loss after tax (from ordinary activities) for the period attributable to members	Down	42.9%	to	(1,029,432)

Net tangible assets per security

	31 December 2020	31 December 2019
Net asset backing (per share)	0.07	0.09

AASB 16 has not had any impact on Anatara's net tangible assets calculation as AASB 16 has not resulted in additional assets being recognised on Anatara's statement of financial position.

Explanation of results

An explanation of the key financial elements contributing to the revenue and result above can be found in the review of operations included within the directors' report.

Distributions

No dividends have been paid during the financial period. The directors do not recommend that a dividend be paid in respect of the financial period (2019: nil).

Changes in controlled entities

N/A

Other information required by Listing Rule 4.2A

N/A

Anatara Lifesciences Ltd

ABN 41 145 239 872

Interim financial report for the half-year 31 December 2020

Directors	Ms Sue MacLeman <i>Non-Executive Chair</i> Dr Jane Ryan <i>Non-Executive Director</i> Dr David Brookes <i>Non-Executive Director</i> Dr Tracie Ramsdale (resigned 26 November 2020) <i>Non-Executive Director</i>
Secretary	Mr Stephen Denaro
Principal registered office in Australia	Level 3, 62 Lygon Street Carlton South VIC 3053 Australia +61 (0)3 9824 5454
Share and debenture register	Computershare Investor Services Pty Limited Level 1, 200 Mary Street Brisbane QLD 4000 +61 (0)7 3237 2100
Auditor	Grant Thornton Audit Pty Ltd Collins Square Tower 5, 727 Collins Street Melbourne VIC 3008 +61 (0)3 8320 2222
Solicitors	Thomson Geer Level 16, Waterfront Place 1 Eagle Street Brisbane QLD 4000
Bankers	Commonwealth Bank of Australia Melbourne VIC 3000
Website	www.anataralifesciences.com

Anatara Lifesciences Ltd

ABN 41 145 239 872

Interim report - 31 December 2020

Contents

	Page
Directors' report	3
Interim financial report	
Consolidated statement of profit or loss and other comprehensive income	7
Consolidated balance sheet	8
Consolidated statement of changes in equity	9
Consolidated statement of cash flows	10
Notes to the consolidated financial statements	11
Directors' declaration	17
Independent auditor's report to the members	18

Your directors present their report on the consolidated entity consisting of Anatara Lifesciences Ltd and the entities it controlled at the end of, or during, the half-year ended 31 December 2020. Throughout the report, the consolidated entity is referred to as the Group.

Directors

The following persons were directors of Anatara Lifesciences Ltd during the whole of the half-year and up to the date of this report:

Ms Sue MacLeman
Dr Jane Ryan
Dr David Brookes
Dr Tracie Ramsdale (resigned 26 November 2020)

Principal activities

The Group is an Australian listed entity that is developing and commercialising innovative, evidence-based products for gastrointestinal health in animals and humans where there is a significant unmet need. Lead products are Detach® for animals and **Gastrointestinal ReProgramming** dietary supplement (GaRP) for humans.

Dividends

No dividends have been paid during the financial period. The directors do not recommend that a dividend be paid in respect of the financial period (2019: \$nil).

Review of operations and financial results

During the half year to 31 December 2020, the Company made significant steps towards taking its first human gastrointestinal health product, **GaRP (Gastrointestinal ReProgramming dietary supplement)**, to market. Expenditure in furthering this effort resulted in a loss after tax of \$1,029,432 for the period (December 2019: \$1,803,324). Anatara is prioritising research and development and commercial development with investment increasing in both areas. General and administrative expenditure was 25% lower than the previous corresponding period.

Human Health

Anatara has developed GaRP to address the unmet need for sufferers of IBS (Irritable Bowel syndrome) and IBD (Inflammatory Bowel disease). Anatara anticipates commencing in early 2021 a randomised, double-blinded, placebo-controlled virtual clinical trial in IBS. The Company considers that future opportunities for evaluation may include functional constipation, functional diarrhoea and functional dyspepsia.

Anatara is planning initiation of a human clinical study on changes to psychological functioning in adults with a moderate level of depression, anxiety or stress symptoms, in response to use of the Company's recently developed colon targeted formulation (3FDC). Anatara has been awarded an Innovation Connections Grant, under the Australian Government's Entrepreneurs' Programme, with funding to be provided to the Commonwealth Scientific and Industrial Research Organisation (CSIRO). This planned study is to be conducted at the CSIRO Nutrition and Health Research Clinic in Adelaide, South Australia. An update will be provided once the timeline for the study is finalised. 3FDC is a subset of Anatara's Gastrointestinal Re-Programming (GaRP) complementary medicine and contains ingredients that are known to have broad ranging effects in the gastrointestinal tract and systemically, including modulation of the gut-brain axis. The proposed study is to evaluate whether 3FDC delivered to the colon affects psychological functioning, specifically assessing for potential improvement in symptoms of anxiety, depression and stress.

Anatara is discussing licensing and commercialisation of GaRP with global consumer health companies. Information about the new potential use of 3FDC, a subset of GaRP, has been made available to these companies.

Review of operations and financial results (continued)

Detach®

Anatara believes that a substantial market opportunity for Detach® exists, with more pressure than ever on producers to reduce their antibiotic use and find suitable alternatives which minimise illnesses, such as scour, on farms. Effective, registered alternatives to antibiotics for scour prevention in piglets are limited.

Anatara has entered into an agreement to initiate a challenge study in weaner piglets with its recently developed bromelain-based formulation (BONIFF). Anatara and Ridley Corporation Ltd (Ridley) have jointly entered into agreements with the Australasian Pork Research Institute Ltd (APRIL) and Murdoch University. APRIL will be providing grant funding for the challenge study "BONIFF-SMEC: An in-field practical delivery mechanism for improved weaner piglet performance". This study is to be conducted by Murdoch University with anticipated target completion of mid-2021. This project aims to test a modified formulation of BONIFF in Semi-Moist Extruded Creep (SMEC) feed on weaning piglets under an enterotoxigenic Escherichia coli (ETEC) challenge model. The project seeks to determine the efficacy of this combined formulation on piglet health, welfare, and performance after weaning.

Anatara successfully completed the poultry challenge trial "Efficacy of ANR-pf on the performance of broilers subject to subclinical and necrotic enteritis challenges". ANR-pf is Anatara's proprietary enriched formulation for poultry in water, designed to allow the full delivery of key additives in a quick and flexible dosing method on-farm even when stock illness is a concern. The study was a randomised, placebo controlled trial of 540 Ross-308 male chicks. The parameters analysed were bird weight gain (WG), feed intake (FI), feed conversion ratio (FCR), and more complex analysis such as an intestinal lesion score of necrosis and ulceration, and oocyst count in the excreta. When analysed over the entire experimental period (0-35 days), treatment with ANR-pf in water provided benefit when compared to untreated birds in weight gain ($p=0.007$), feed intake ($p=0.039$), as well as lesion scores in both the jejunum ($p=0.040$) and ileum ($p=0.035$), and oocyst shedding ($p < 0.05$). The difference in feed conversion rate was also improved, though failed to reach statistical significance.

Commercial focus

Looking ahead, Anatara is coming into exciting time in the Company's history. Over the next 6-12 months, the Company is targeting to:

- undertake a human clinical study with GaRP in IBS patients this year;
- complete the BONIFF-SMEC piglet challenge study for enterotoxigenic Escheria coli by the middle of this calendar year; and
- announce a partnering deal for GaRP by the middle of this calendar year.

Significant changes in the state of affairs

Dr Tracie Ramsdale retired by rotation at the AGM in accordance with Listing Rule 14.5 and rule 19.3(a) of the Company's constitution and did not seek re-election. There have been no other significant changes in the state of affairs of the group during the period.

Events since the end of the financial year

On 8 February 2021, Anatara Lifesciences Limited (ASX:ANR) (Anatara) acquired a total of 211,413 shares for \$37,631.52 under the Buy-Back Facility at the Buy-Back Price and these shares have been cancelled in accordance with the Corporations Act 2001 (Cth). As a result, Anatara has 70,238,523 fully paid ordinary shares on issue.

Auditor's independence declaration

A copy of the auditor's independence declaration as required under section 307C of the *Corporations Act 2001* is set out on page 6.

This report is made in accordance with a resolution of directors.

A handwritten signature in black ink, appearing to be 'Sue MacLeman', written over a horizontal line.

Ms Sue MacLeman
Director

Melbourne
23 February 2021

Auditor's Independence Declaration

To the Directors of Anantara Lifesciences Ltd

In accordance with the requirements of section 307C of the *Corporations Act 2001*, as lead auditor for the review of Anantara Lifesciences Ltd for the half-year ended 31 December 2020, I declare that, to the best of my knowledge and belief, there have been:

- a no contraventions of the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- b no contraventions of any applicable code of professional conduct in relation to the review.



Grant Thornton Audit Pty Ltd
Chartered Accountants



T S Jackman
Partner – Audit & Assurance

Melbourne, 23 February 2021

Anatara Lifesciences Ltd
Consolidated statement of profit or loss and other comprehensive income
For the half-year 31 December 2020

	Notes	Consolidated entity	
		31 December 2020	31 December 2019
		\$	\$
Other income	4	685,611	417,352
General and administrative expenses	4	(1,221,476)	(1,628,165)
Research and development expenses		(496,667)	(626,771)
Operating loss		(1,032,532)	(1,837,584)
Finance income		3,100	34,260
Loss before income tax		(1,029,432)	(1,803,324)
Income tax expense		-	-
Loss for the period		(1,029,432)	(1,803,324)
Other comprehensive income			
Total comprehensive loss for the period		(1,029,432)	(1,803,324)
		Cents	Cents
Earnings per share for profit from continuing operations attributable to the ordinary equity holders of the company:			
Basic earnings per share	7	(1.64)	(3.64)
Diluted earnings per share	7	(1.64)	(3.64)

The above consolidated statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes.

Anatara Lifesciences Ltd
Consolidated balance sheet
As at 31 December 2020

		Consolidated entity	
		31 December	30 June
		2020	2020
Notes		\$	\$
ASSETS			
Current assets			
	Cash and cash equivalents*	3,675,097	2,682,368
	Other current assets	101,002	23,740
5	Trade and other receivables	1,263,656	630,333
	Total current assets	5,039,755	3,336,441
Non-current assets			
	Property, plant and equipment	3,850	7,187
	Total non-current assets	3,850	7,187
	Total assets	5,043,605	3,343,628
LIABILITIES			
Current liabilities			
	Trade and other payables	167,584	412,355
	Employee benefit obligations	68,127	51,679
	Total current liabilities	235,711	464,034
Non-current liabilities			
	Employee benefit obligations	29,564	22,929
	Total non-current liabilities	29,564	22,929
	Total liabilities	265,275	486,963
	Net assets	4,778,330	2,856,665
EQUITY			
6	Contributed equity	19,792,182	17,039,590
6	Other reserves	623,714	553,342
	Retained earnings	(15,637,566)	(14,736,267)
	Total equity	4,778,330	2,856,665

* Term deposits with a short maturity period of 90 days or less are included in cash and cash equivalents balance.

The above consolidated balance sheet should be read in conjunction with the accompanying notes.

Anatara Lifesciences Ltd
Consolidated statement of changes in equity
For the half-year 31 December 2020

	Attributable to owners of Anatara Lifesciences Ltd			Total equity \$
	Share capital \$	Share options and performance rights reserve \$	Accumulated losses \$	
Consolidated entity				
Balance at 1 July 2019	16,941,392	499,070	(11,524,895)	5,915,567
Loss for the period	-	-	(1,803,324)	(1,803,324)
Total comprehensive income for the half-year	-	-	(1,803,324)	(1,803,324)
Transactions with owners in their capacity as owners:				
Share based payment expense - options	-	56,777	-	56,777
Issued capital	74,573	-	-	74,573
Share based payment expense - performance rights	-	23,625	-	23,625
	<u>74,573</u>	<u>80,402</u>	<u>-</u>	<u>154,975</u>
Balance at 31 December 2019	17,015,965	579,472	(13,328,219)	4,267,218
Balance at 1 July 2020	17,039,590	553,342	(14,736,267)	2,856,665
Loss for the period	-	-	(1,029,432)	(1,029,432)
Total comprehensive income for the half-year	-	-	(1,029,432)	(1,029,432)
Transactions with owners in their capacity as owners:				
Issued capital	6(a) 3,070,005	-	-	3,070,005
Less: Capital raising costs	(334,825)	-	-	(334,825)
Share based payment expense - options	6(c) -	215,917	-	215,917
Performance rights exercised	6(b) 17,412	(17,412)	-	-
Options forfeited/lapsed	6(c) -	(128,133)	128,133	-
	<u>2,752,592</u>	<u>70,372</u>	<u>128,133</u>	<u>2,951,097</u>
Balance at 31 December 2020	19,792,182	623,714	(15,637,566)	4,778,330

The above consolidated statement of changes in equity should be read in conjunction with the accompanying notes.

Anatara Lifesciences Ltd
Consolidated statement of cash flows
For the half-year 31 December 2020

	Consolidated entity	
	31 December	31 December
	2020	2019
Notes	\$	\$
Cash flows from operating activities		
Payments to suppliers and employees (inclusive of GST)	(1,993,088)	(2,026,845)
Interest received	6,750	72,480
Government grants and tax incentives	90,840	847,326
Net cash outflow from operating activities	(1,895,498)	(1,107,039)
Cash flows from investing activities		
Payments for property, plant and equipment	-	(3,088)
Payments for investment in term deposits	-	(1,000,000)
Proceeds from withdrawal from term deposits	-	4,550,000
Net cash inflow from investing activities	-	3,546,912
Cash flows from financing activities		
Proceeds from issues of shares and other equity securities	6(a) 3,070,005	-
Share issue transaction costs	(181,778)	-
Net cash inflow from financing activities	2,888,227	-
Net increase in cash and cash equivalents	992,729	2,439,873
Cash and cash equivalents at the beginning of the financial year	2,682,368	5,410,077
Cash and cash equivalents at end of the half-year	3,675,097	7,849,950

The above consolidated statement of cash flows should be read in conjunction with the accompanying notes.

1 Segment information

Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer of Anatara Lifesciences Ltd. The group has identified one reportable segment; that is, the research, development of oral solutions for gastrointestinal diseases and the commercialisation of the Detach diarrhoea treatment for piglets. The segment details are therefore fully reflected in the body of the financial statements.

2 Basis of preparation of half-year report

This consolidated interim financial report for the half-year reporting period ended 31 December 2020 has been prepared in accordance with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Act 2001*.

These interim report does not include all the notes of the type normally included in an annual financial report. Accordingly, this report is to be read in conjunction with the annual report for the year ended 30 June 2020 and any public announcements made by Anatara Lifesciences Ltd during the interim reporting period in accordance with the continuous disclosure requirements of the *Corporations Act 2001*.

The interim financial statements have been approved and authorised for issue by the board of directors on 23 February 2020.

(a) New and amended standards adopted by the Group

The Company has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

Any new or amended Accounting Standards or Interpretations that are not yet mandatory have not been early adopted.

(b) Going concern

The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business activities and the realisation of assets and settlement of liabilities in the normal course of business.

As disclosed in the financial statements, the Group incurred a loss of \$1,029,432 and had operating cash outflows of \$1,895,498 for the reporting period ended 31 December 2020. As at 31 December 2020, the Group's held cash and cash equivalents of \$3,675,097. The Group raised \$2,735,180 in capital, net of costs, during the period. On 3 February 2021, the Group received an R&D Tax Incentive refund of \$888,049.

In the process of approving the Group's internal forecast and business plan for upcoming financial years, the board has considered the cash position of the Group within the next 12 months from the date of this report. The Group's internal forecast and business plan for the upcoming financial year does not include capital raising.

The board has assessed the resources and opportunities available to the Group, and consequently believe that the Group will be able to repay its debts as and when they fall due and are of the opinion that the financial statements have been appropriately prepared on a going concern basis.

3 Estimates

When preparing the Interim Financial Statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The actual results may differ from the judgements, estimates and assumptions made by management, and will seldom equal the estimated results.

The judgements, estimates and assumptions applied in the Interim Financial Statements, including the key sources of estimation uncertainty, were the same as those applied in the Group's last annual financial statements for the year ended 30 June 2020.

4 Other income and expense items

(a) Other income

	Consolidated entity	
	31 December 2020	31 December 2019
	\$	\$
Research and development tax incentive	596,029	417,352
Other grants	89,582	-
	685,611	417,352

(b) Breakdown of expenses by nature

	31 December 2020	31 December 2019
	\$	\$
Accounting and audit	54,661	63,494
Consulting	109,567	143,709
Depreciation	3,337	10,395
Employee benefits	708,336	924,072
Insurance	28,582	29,306
Investor relations	7,934	92,247
Legal	26,122	20,635
Listing and share registry	62,243	43,399
Occupancy	29,657	49,654
Share-based payments	62,870	78,673
Superannuation	57,526	77,359
Travel and entertainment	(151)	23,422
Other	70,792	71,800
General and administrative expenses	1,221,476	1,628,165

5 Financial assets and financial liabilities

(a) Trade and other receivables

	Consolidated entity					
	31 December 2020			30 June 2020		
	Current \$	Non- current \$	Total \$	Current \$	Non- current \$	Total \$
Accrued receivables (i)	1,210,212	-	1,210,212	630,333	-	630,333
Other receivables	53,444	-	53,444	-	-	-
	1,263,656	-	1,263,656	630,333	-	630,333

(i) Accrued receivables include \$1,208,996 from the Australian Taxation Office in relation to the R&D tax incentive and \$1,216 interest income from deposits at call.

6 Equity

(a) Share capital

	31 December 2020 No.	30 June 2020 No.	31 December 2020 \$	30 June 2020 \$
Ordinary shares Fully paid	70,449,936	49,856,177	19,792,182	17,039,590

(i) Movements in ordinary shares

Details	Number of shares	\$
Balance at 1 July 2020	49,856,177	17,039,590
Shares issued	20,466,667	3,070,005
Less: Transaction costs arising on share issue	-	(334,825)
Exercise of performance rights with nil cash consideration 15 September 2020	72,363	7,498
Exercise of performance rights with nil cash consideration 28 October 2020	54,729	9,914
Balance at 31 December 2020	70,449,936	19,792,182

Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the group in proportion to the number of and amounts paid on the shares held.

On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote.

6 Equity (continued)

(b) Performance rights reserve

	31 December 2020 No.	30 June 2020 No.	31 December 2020 \$	30 June 2020 \$
Performance rights	780,985	-	106,996	124,408
<i>(i) Movements in performance rights</i>				
Details			Number of performance rights	\$
Opening balance			-	124,408
Performance rights issued to Executive Management on 11 August 2020 (*)			908,077	-
Exercised of performance rights			(127,092)	(17,412)
Balance at 31 December 2020			780,985	106,996

(*) Performance rights issued to the staff under Anatara Executive Option Plan issued in lieu of cash bonuses.

(c) Options reserve

	31 December 2020 No.	30 June 2020 No.	31 December 2020 \$	30 June 2020 \$
Options	2,963,704	2,920,412	516,718	428,934
<i>(i) Movement in options</i>				
			Number of shares	\$
Opening balance 1 July 2019			2,571,000	499,070
Issue of unlisted option at \$0.2305 22 June 2020			761,912	4,608
Share-based payment expenses of previously issued options			-	81,646
Options cancelled during the year			(412,500)	(156,390)
Balance 30 June 2020			2,920,412	428,934
Options issued during the period			2,117,704	199,807
Share-based payment expenses of previously issued options			-	16,110
Forfeited/lapsed during the period			(1,312,500)	(127,875)
Adjust issuance of unlisted option at \$0.2305 22 June 2020			(761,912)	(258)
Balance 31 December 2020			2,963,704	516,718

7 Loss per share

Both the basic and diluted loss per share have been calculated using the profit attributable to shareholders of Anatara as the numerator, i.e. no adjustments to profits were necessary during the six months period to 31 December 2020 and 2019.

The weighted average number of shares for the purposes of the calculation of diluted loss per share has not been adjusted, as share options on issue are antidilutive.

(a) Basic/diluted loss per share

	Consolidated entity	
	31 December 2020	31 December 2019
	Cents	Cents
Basic loss per share	(1.64)	(3.64)
Diluted loss per share	(1.64)	(3.64)

(b) Reconciliation of loss used in calculating loss per share

	Consolidated entity	
	31 December 2020	31 December 2019
	\$	\$
<i>Basic and diluted loss per share</i>		
Loss attributable to the ordinary equity holders of the Group used in calculating basic loss per share:		
From continuing operations	(1,029,432)	(1,803,324)

(c) Weighted average number of shares used as denominator

	Consolidated entity	
	2020	2019
	Number	Number
Weighted average number of ordinary shares used as the denominator in calculating basic and diluted loss per share	62,789,280	49,494,850

8 Events occurring after the reporting period

Buy-back of unmarketable parcels of shares

Anatara Lifesciences Limited (ASX:ANR) (Anatara) instituted an off-market share buy-back facility (Buy-Back Facility) to buy-back all the shares held by shareholders who held unmarketable parcels of shares in Anatara (Eligible Shareholders) on 11 December 2020 (Record Date).

Under the Listing Rules of the Australian Securities Exchange (ASX), any shareholding in Anatara valued at less than \$500 is considered to be an "unmarketable parcel" of shares. Based on the closing price of \$0.19 per share as at the Record Date, an unmarketable parcel of shares in Anatara is any shareholding of 2,631 shares or less. Anatara shareholders who held 2,631 shares or more as at the Record Date will not be eligible to participate in the Buy-Back Facility.

On 8 February 2021, a total of 211,413 Anatara shares were acquired for \$37,631.52 under the Buy-Back Facility at the Buy-Back Price and have been cancelled in accordance with the Corporations Act 2001 (Cth). As a result, Anatara has 70,238,523 fully paid ordinary shares on issue.

9 COVID-19 impact on business

Anatara Lifesciences remains committed to its corporate strategy and focused on delivering on its anticipated milestones during the year ahead. However, the Company is actively planning for disruptions that may lead to delays in meeting some of these objectives.

The company received financial support from Federal Government incentives through Cashflow Boost and, through payroll tax refunds and deferrals by state governments. Anatara recorded other income of \$42,082 for these items. Anatara did not participate in JobKeeper and has not terminated any employees during this period. Anatara employees have been able to continue laboratory-based activities and as a result have advanced GaRP to being clinical trial ready.

**Anatara Lifesciences Ltd
Directors' declaration
31 December 2020**

In the directors' opinion:

- (a) the financial statements and notes set out on pages 2 to 16 are in accordance with the *Corporations Act 2001*, including:
 - (i) complying with AASB 134 *Interim Financial Reporting*, the *Corporations Regulations 2001* and other mandatory professional reporting requirements, and
 - (ii) giving a true and fair view of the consolidated entity's financial position as at 31 December 2020 and of its performance for the half-year ended on that date, and
- (b) there are reasonable grounds to believe that the Anatara Lifesciences Ltd will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of directors.



Ms Sue MacLeman
Director

Melbourne
23 February 2021

Independent Auditor's Review Report

To the Members of Anataara Lifesciences Ltd

Report on the review of the half year-financial report

Conclusion

We have reviewed the accompanying half-year financial report of Anataara Lifesciences Ltd (the Company) and its subsidiaries (the Group), which comprises the consolidated statement of financial position as at 31 December 2020, and the consolidated statement of profit or loss and other comprehensive income, consolidated statement of changes in equity and consolidated statement of cash flows for the half year ended on that date, a description of accounting policies, other selected explanatory notes, and the directors' declaration.

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the accompanying half-year financial report of Anataara Lifesciences Ltd does not comply with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the [name of entity's] financial position as at 31 December 2020 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

Basis for Conclusion

We conducted our review in accordance with ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*. Our responsibilities are further described in the Auditor's Responsibilities for the Review of the Financial Report section of our report. We are independent of the Company in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the annual financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

Directors' responsibility for the half year financial report

The Directors of the Company are responsible for the preparation of the half year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the Directors determine is necessary to enable the preparation of the half year financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

Auditor's responsibility

Our responsibility is to express a conclusion on the half year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half year financial report is not in accordance with the *Corporations Act 2001* including giving a true and fair view of the Group's financial position as at 31 December 2020 and its performance for the half year ended on that date, and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*.

A review of a half year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Grant Thornton Audit Pty Ltd
Chartered Accountants



T S Jackman
Partner – Audit & Assurance

Melbourne, 23 February 2021